Ticker > Company >

Ajanta Pharma share price

Ajanta Pharma Ltd.

NSE: AJANTPHARM BSE: 532331 SECTOR: Pharmaceuticals & Drugs  106k   526   55

2614.75
-1.05 (-0.04%)
BSE: 02 Apr 04:01 PM

Price Summary

Today's High

₹ 2646.25

Today's Low

₹ 2584.45

52 Week High

₹ 3485.75

52 Week Low

₹ 2049.75

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

32661.39 Cr.

Enterprise Value

32598.33 Cr.

No. of Shares

12.49 Cr.

P/E

36.86

P/B

8.64

Face Value

₹ 2

Div. Yield

1.95 %

Book Value (TTM)

₹  302.77

CASH

63.06 Cr.

DEBT

0 Cr.

Promoter Holding

66.26 %

EPS (TTM)

₹  70.94

Sales Growth

16.41%

ROE

24.26 %

ROCE

33.15%

Profit Growth

44.48 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Ajanta Pharma Ltd.

Met XL Softdrops Sunstop Kamagra Melacare Cinod Feburic Forticord Zaha Ilapro

Index Presence

The company is present in 25 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year16.41%
3 Year13.46%
5 Year17.51%

Profit Growth

1 Year44.48%
3 Year6.11%
5 Year15.56%

ROE%

1 Year24.26%
3 Year21.82%
5 Year21.98%

ROCE %

1 Year33.15%
3 Year28.39%
5 Year29.24%

Debt/Equity

0

Price to Cash Flow

44.42

Interest Cover Ratio

162.3162

CFO/PAT (5 Yr. Avg.)

0.868625081574601

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 66.26 11.17
Sep 2024 66.26 11.17
Jun 2024 66.27 11.57
Mar 2024 66.21 12.26
Dec 2023 66.21 12.33
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 21.8227398803044% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.3921139897195% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 162.3162.
  • The Company has been maintaining an effective average operating margins of 26.5557880142132% in the last 5 years.
  • Company’s PEG ratio is 0.828628083607045.
  • The company has an efficient Cash Conversion Cycle of 7.50989999999999 days.
  • Company has a healthy liquidity position with current ratio of 3.8666.

 Limitations

  • The company has shown a poor profit growth of 6.11149666809405% for the Past 3 years.
  • The company has shown a poor revenue growth of 13.4634235238538% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 1085.29 926.07 1077.27 1128.91 1101.92
Total Expenditure 758.11 698.92 761.44 826 765.59
Operating Profit 327.18 227.15 315.83 302.91 336.33
Other Income 13.73 33.68 28.37 40.34 33.23
Interest 2.36 1.42 0.72 0.73 2.48
Depreciation 33.41 33.47 32.92 33.32 34.93
Exceptional Items 0 0 0 0 0
Profit Before Tax 305.14 225.94 310.56 309.2 332.15
Tax 84.99 63.25 74.53 74.22 79.7
Profit After Tax 220.15 162.69 236.03 234.98 252.45
Adjusted EPS (Rs) 17.42 12.88 18.83 18.75 20.14

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 2196.42 2718.59 3140.64 3411.27 3971.12
Total Expenditure 1663.64 1801.68 2249.75 2711.99 2851.69
Operating Profit 532.78 916.91 890.89 699.28 1119.43
Other Income 184.2 103.57 139.73 132.75 116.48
Interest 9.1 6.9 9.12 5.23 6.8
Depreciation 91.29 111.49 120.96 126.95 132.16
Exceptional Items -3.92 0 0 0 0
Profit Before Tax 612.67 902.09 900.54 699.85 1096.95
Tax 171.54 226.45 180.68 141.13 289.71
Net Profit 441.13 675.64 719.86 558.72 807.24
Adjusted EPS (Rs.) 33.71 52.07 56.2 44.38 64.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 17.54 17.39 17.17 25.27 25.27
Total Reserves 2443.76 2867.59 3152.01 3221.18 3388.3
Borrowings 0 0 0 0 0
Other N/C liabilities 252.27 321.18 338.33 272.9 174.17
Current liabilities 614.3 706.28 469.7 907.84 629.19
Total Liabilities 3327.87 3912.44 3977.21 4427.19 4217.44
Assets
Net Block 1439.93 1509.89 1483.91 1484.01 1464.89
Capital WIP 131.06 108.19 152.86 209.47 256.45
Intangible WIP 0 0 0 0 0
Investments 18.63 17.89 42.99 42.99 37.09
Loans & Advances 165.33 230.52 226.15 134.68 12.97
Other N/C Assets 18.48 19.55 14.29 12.77 13.22
Current Assets 1554.44 2026.4 2057.01 2543.27 2432.82
Total Assets 3327.87 3912.44 3977.21 4427.19 4217.44
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 612.67 902.09 900.54 699.85 1096.95
Adjustment -36.6 37.07 55.58 79.34 49.31
Changes in Assets & Liabilities -136.66 -274.26 -220.31 82.66 -158.63
Tax Paid -138.53 -197.91 -193.47 -125.56 -252.28
Operating Cash Flow 300.88 466.99 542.34 736.29 735.35
Investing Cash Flow -115.91 -162.68 -66.04 -501.31 105.02
Financing Cash Flow -134 -268.9 -457.3 -105.12 -1047.7
Net Cash Flow 50.97 35.41 19 129.86 -207.33

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
promoters 66.21 66.21 66.27 66.26 66.26
aayush m agrawal 0.02 0.02 0.02 0.02 0.02
aayush m agrawal, trustee... 11.31 11.31 11.30 11.30 11.30
gabs investments pvt ltd 10.00 10.00 10.08 10.08 10.08
ganga exports being repre... 2.68 2.68 2.68 2.68 2.68
rajesh m agrawal, trustee... 14.48 14.48 14.48 14.47 14.47
ravi p agrawal 0.23 0.23 0.23 0.23 0.23
ravi p agrawal, trustee r... 13.01 13.01 13.01 13.00 13.00
yogesh m agrawal, trustee... 14.48 14.48 14.48 14.47 14.47
PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
investors 33.79 33.79 33.73 33.74 33.74
canara robeco mutual fund... - - - 1.03 1.09
hdfc large and mid cap fu... - 1.04 1.13 1.54 1.47
investor education and pr... - 0.09 0.09 - 0.09
kotak small cap fund 1.23 1.24 1.24 1.24 1.24
llp 0.04 0.03 0.03 0.03 0.02
nippon life india trustee... 3.12 2.99 3.04 2.98 2.99
tata aia life insurance c... 1.64 1.65 1.67 1.34 1.24
uti flexi cap fund 3.16 3.08 3.03 2.95 2.86
aditya birla sun life tru... - - - 1.05 -
investor education and pr... 0.09 - - 0.09 -
invesco india contra fund... 1.03 - - - -

Ratings & Research Reports

Company Presentations

Company News

Ajanta Pharma to expand manufacturing capacity 21 Mar, 2:09 PM Ajanta Pharma informs about updates 20 Mar, 5:26 PM Ajanta Pharma informs about disclosure 11 Mar, 12:01 PM Ajanta Pharma informs about disclosure 14 Feb, 11:53 AM Ajanta Pharma informs about analyst meet 7 Feb, 10:00 AM Ajanta Pharma informs about clarification on market price movement 4 Feb, 10:12 AM Ajanta Pharma - Quaterly Results 30 Jan, 3:35 PM Ajanta Pharma - Quaterly Results 30 Jan, 3:35 PM Ajanta Pharma - Quaterly Results 30 Jan, 3:35 PM Ajanta Pharma - Quaterly Results 28 Oct, 3:51 PM Ajanta Pharma - Quaterly Results 28 Oct, 3:51 PM Ajanta Pharma - Quaterly Results 28 Oct, 3:51 PM Ajanta Pharma informs about disclosure 10 Sep, 2:10 PM Ajanta Pharma informs about loss of share certificate 23 Aug, 2:13 PM Ajanta Pharma informs about disclosure 21 Aug, 5:29 PM Ajanta Pharma informs about participation in investor conference 8 Aug, 2:25 PM Ajanta Pharma reports 18% rise in Q1 consolidated net profit 30 Jul, 5:19 PM Ajanta Pharma - Quaterly Results 30 Jul, 3:01 PM Ajanta Pharma - Quaterly Results 30 Jul, 3:01 PM Ajanta Pharma - Quaterly Results 30 Jul, 3:01 PM Ajanta Pharma informs about board meeting 17 Jul, 3:14 PM Ajanta Pharma informs about compliances-certificate 11 Jul, 2:24 PM Ajanta Pharma informs about annual report and BRSR 18 Jun, 5:34 PM Ajanta Pharma informs about newspapers publication 17 Jun, 4:29 PM Ajanta Pharma informs about disclosure 4 Jun, 12:37 PM Ajanta Pharma - Quaterly Results 2 May, 4:39 PM Ajanta Pharma - Quaterly Results 2 May, 4:39 PM Ajanta Pharma - Quaterly Results 2 May, 4:39 PM Ajanta Pharma informs about compliance certificate 15 Apr, 4:53 PM Ajanta Pharma informs about disclosure 30 Mar, 3:27 PM Ajanta Pharma - Quaterly Results 31 Jan, 4:12 PM Ajanta Pharma - Quaterly Results 31 Jan, 4:12 PM Ajanta Pharma - Quaterly Results 31 Jan, 4:12 PM Ajanta Pharma submits intimation of record date 25 Jan, 12:53 PM Ajanta Pharma informs about update on board meeting 25 Jan, 10:58 AM Ajanta Pharma informs about loss of share certificate 19 Dec, 1:39 PM Ajanta Pharma informs about loss of share certificate 15 Dec, 2:12 PM Ajanta Pharma informs about disclosure 15 Dec, 12:22 PM Ajanta Pharma informs about revised disclosure 15 Dec, 12:14 PM Ajanta Pharma informs about disclosures 24 Nov, 5:05 PM Ajanta Pharma informs about loss of share certificate 22 Nov, 10:43 AM Ajanta Pharma - Quaterly Results 31 Oct, 2:15 PM Ajanta Pharma - Quaterly Results 31 Oct, 2:15 PM Ajanta Pharma - Quaterly Results 31 Oct, 2:15 PM Ajanta Pharma informs about board meeting 19 Oct, 3:17 PM Ajanta Pharma informs about loss of share certificate 27 Sep, 11:32 AM Ajanta Pharma informs about newspaper publication 4 Sep, 11:06 AM Ajanta Pharma gets USFDA’s final nod for Topiramate Extended-Release Capsules 30 Aug, 6:15 PM Ajanta Pharma informs about investor meetings 17 Aug, 10:12 AM Ajanta Pharma informs about details of loss of certificate 7 Aug, 4:20 PM

Ajanta Pharma Stock Price Analysis and Quick Research Report. Is Ajanta Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ajanta Pharma and its performance over the period of time. Ajanta Pharma stock price today is Rs 2617.75.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ajanta Pharma cash from the operating activity was Rs 735.35 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ajanta Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ajanta Pharma , the EPS growth was 44.4803 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ajanta Pharma has OPM of 28.1892765768851 % which is a good sign for profitability.
     
  • ROE: Ajanta Pharma have a healthy ROE of 24.2638 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ajanta Pharma is Rs 2617.75. One can use valuation calculators of ticker to know if Ajanta Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Ajanta Pharma
X